

Express Mail Label No. EL 933049160 US
Docket No. 57109 (71699)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: S. Denmeade, et al.
U.S.S.N.: 09/627,600 Group: 1655
FILED: July 28, 2000 Confirmation No.: 3631
FOR: ACTIVATION OF PEPTIDE PRODRUGS BY (HK2)

Box Sequence
Commissioner for Patents
Washington, DC 20231

SIR:

LETTER

Applicants wish to bring to the attention of the Patent Office the following address
change for the Agent.

Agent's old correspondence address:

Fish & Richardson, P.C.
45 Rockefeller Plaza
Suite 2800
New York, New York
Telephone: (212) 765-5070
Facsimile: (212) 258-2291

COPY

Agent's new correspondence address:


EDWARDS & ANGELL, LLP
Dike, Bronstein, Roberts & Cushman
Intellectual Property Practice Group
P.O. Box 9169
Boston, Massachusetts 02209
Telephone: (617) 439-4444
Facsimile: (617) 439-4170

Applicants kindly ask that this address change for Agent be made of record in the above-identified application.

Please charge any fees that may be due in connection with this matter to Deposit Account 04-1105.

Please contact the undersigned attorney if any additional information is needed.

Respectfully submitted,



Dianne M. Rees, Ph.D. (Reg. No. 45,281)
Intellectual Property Group of
EDWARDS & ANGELL, LLP
P.O. Box 9169
Boston, MA 02209
(617) 439-4444

Customer No. 21874

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: S. Denmeade, et al. Examiner: S. Liu
Application No.: 09/627,600 Group: 1653
Filed: July 28, 2000
For: ACTIVATION OF PEPTIDE PRODRUGS BY (HK2)

RECEIVED
TECH CENTER 1600/2900
03 MAY 27 PM 5:17

VIA HAND DELIVERY
MAIL STOP SEQUENCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

RECEIVED
JUN 02 2003
TECH CENTER 1600/2900

TRANSMITTAL LETTER

Transmitted herewith for filing in the above-referenced patent application are the following documents:


1. Associate Power of Attorney (1 page);
2. Supplemental Response to Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures (2 pages);
3. Copy of Response filed on July 18, 2002 (49 pages);
4. Copy of Return Receipt Postcard (1 page);
5. Copy of Facsimile from Examiner S. Liu (5 pages);
6. This transmittal letter (1 page) (x2); and
7. Return Receipt Postcard.

The Commissioner is hereby authorized to charge any excess fees that may be required, or credit any overpayment to Deposit Account No. 04-1105. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Date: May 23, 2003

By:


Jennifer K. Rosenfield, Reg. No. 53,531
Intellectual Property Practice Group of
Edwards & Angell, LLP
P.O. Box 9169
Boston, MA 02209
Tele: (617)-439-4444

Customer No. 21874

Attorney Docket No. 57109 (71699)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of: S. Denmeade, et al. Examiner: S. Liu
Application No.: 09/627,600 Group: 1653
Filed: July 28, 2000
For: ACTIVATION OF PEPTIDE PRODRUGS BY (HK2)

RECEIVED
TECH CENTER 1600/2900
03 MAY 27 PM 5:17

VIA HAND DELIVERY
MAIL STOP SEQUENCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED
JUN 02 2003

TECH CENTER 1600/2900

Sir:

ASSOCIATE POWER OF ATTORNEY (37 CFR 1.34)


The undersigned has power of attorney in the above referenced application.
Please recognize the following as an Associate Agent in this case:

Jennifer K. Rosenfield, Reg. No. 53,531

Respectfully submitted,

Date: May 23, 2003

By:


Peter F. Corless, Reg. No. 33,860
Intellectual Property Practice Group of
Edwards & Angell, LLP
P.O. Box 9169
Boston, MA 02209
Tele: (617)-439-4444

Customer No. 21,874

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S)	S. Denmeade, et al.	EXAMINER:	S. Liu
U.S.S.N.:	09/627,600	GROUP:	1653
FILED (U.S.):	July 28, 2000	Conf. No.	3631
FOR:	ACTIVATION OF PEPTIDE PRODRUGS BY (HK2)		

VIA HAND DELIVERY

MAIL STOP SEQUENCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

RECEIVED
TECH CENTER 1600/2900
03 MAY 27 PM 5:17

JUN 02 2003

TECH CENTER 1600/2900

**SUPPLEMENTAL RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS
FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR
AMINO ACID SEQUENCE DISCLOSURES**

Dear Sir:

Applicants thank the Examiner for the courtesy of the telephone conference on May 1, 2003 regarding the above-referenced application. According to the Examiner, the U.S. Patent and Trademark Office had not received a Response to the outstanding Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acid Sequence Disclosures ("the Notice") dated July 3, 2002 for the above-referenced patent application.

Applicants submit that a Response to the Notice was timely filed by Applicants on July 18, 2002. As evidence of the timely response, Applicants submit herewith true copies of the following documents:

1. A copy of the Response filed on July 18, 2002, including all associated paperwork, as well as the sequence listing in computer readable form (CRF).

Attorney Docket No. 57109 (71699)
U.S.S.N. 09/627,600
Filed (U.S.): July 28, 2000
Page 2 of 2


2. A copy of the return receipt postcard submitted with the above-referenced Response, date stamped by the Patent Office on July 18, 2002.
3. A copy of a facsimile received by Applicants' agent, sent by Examiner Liu on May 1, 2003. The second page of this facsimile, which corresponds to the front page of the Notice, contains the docketing stamp of Applicants' agent, Edwards & Angell, LLP. The presence of this docketing stamp indicates that this copy of the Notice must have originated with Applicants' agent as part of a Response to the Notice, and accordingly proves that a Response to the Notice must have been filed and received by the Patent Office. Additionally, there is a Tech Center 1600/2900 "Received" stamp on this copy of the Notice, indicating that the Response was indeed received by the Patent Office.

Based on the foregoing evidence, Applicants submit that a Response to the Notice was timely filed and received by the Patent Office, and respectfully request that the enclosed copy of the Response be entered in the application.

The Commissioner is hereby authorized to charge any excess fees that may be required, or credit any overpayment to Deposit Account No. 04-1105. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

Date: May 23, 2003


Jennifer Rosenfield, Reg. No. 53,531
Intellectual Property Practice Group of
EDWARDS & ANGELL LLP
P.O. Box 9169
Boston, MA 02209

Express Mail Label No. EL 933049160 US
Attorney Docket No. 57109 (71699)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANT(S)	S. Denmeade, et al.	EXAMINER:	S. Liu
U.S.S.N.:	09/627,600	GROUP:	1653
FILED (U.S.):	July 28, 2000	Conf. No.	3631
FOR:	ACTIVATION OF PEPTIDE PRODRUGS BY (HK2)		

RECEIVED
JUN 02 2003
TECH CENTER 1600/20

BOX SEQUENCE
Commissioner for Patents
Washington, D.C. 20231

COPY

Sir/Madam:

**RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID
SEQUENCE DISCLOSURES**

The following is in response to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed July 3, 2002, in the above-referenced application.

Enclosed herewith for filing in the subject application are the following:

1. Paper Copy of Sequence Listing previously submitted;
2. New Computer Readable Form (CRF) of Sequence Listing;
3. Copy of Notice To Comply With Requirements For Patent Applications Containing Nucleotide Sequence And/Or Amino Acids Sequence Disclosures;
4. Copy of Error Report indicating unreadable disc;
5. Amendment directing entry of Paper Copy of Sequence Listing into specification [included in this paper];
6. Statement Accompanying Submission Of Sequence Listing Under 37 C.F.R. § 1.821(g) (included in this paper);
7. Associate Power of Attorney; and
8. Change of Correspondence Address.

Attorney Docket No. 57109 (71699)
U.S.S.N. 09/627,600
Filed (U.S.): July 28, 2000
Page 2 of 2

AMENDMENT DIRECTING ENTRY OF SEQUENCE LISTING

At the last page of the specification, please enter the attached paper copy of the Sequence Listing (25 pages) and number the pages as appropriate.

STATEMENT ACCOMPANYING SUBMISSION OF SEQUENCE LISTING

Provided herewith is a Paper Copy of a Sequence Listing for the nucleotide and/or amino acid sequence(s) in this application. Each Sequence has been assigned a separate identifier as required in 37 C.F.R. § 1.821(c) and 37 C.F.R. §§ 1.822 and 1.823. An amendment directing entry of the Paper Copy of the Sequence Listing into the specification is provided above.

Applicants further provide a Computer Readable Form (CRF) corresponding to the Paper Copy of the Sequence Listing provided herewith. Pursuant to 37 C.F.R. § 1.821(g), Applicants' agent hereby states that the CRF corresponds exactly to the Paper Copy of the Sequence Listing provided herewith. Applicants' agent further hereby states that the contents of the Paper Copy of the Sequence Listing and CRF do not go beyond the disclosure in the Application as filed and do not introduce new matter.

If for any reason, the fee paid is inadequate or credit is owed for any excess fee paid, you are hereby authorized and requested to charge Deposit Account No. **04-1105**.

Date: July 18, 2002

Respectfully submitted,

Dianne M. Rees
Dianne M. Rees, Ph.D.
(Reg. No. 45,281)
EDWARDS & ANGELL, LLP
P.O. Box 9169
Boston, MA 02209

Telephone: 617-439-4444
Customer No. 21874
BOS2_307161.1